Bicyclic-azaarylmethoxy) indoles as inhibitors of leukotriene
申请人:Merck Frosst Canada Inc.
公开号:US05273980A1
公开(公告)日:1993-12-28
Compounds having the formula I: ##STR1## are inhibitors of leukotriene biosynthesis. These compounds are useful as anti-asthmatic, anti-allergic, anti-inflammatory, and cytoprotective agents. They are also useful in treating diarrhea, hypertension, angina, platelet aggregation, cerebral spasm, premature labor, spontaneous abortion, dysmenorrhea, and migraine.
(Bicyclic-azaarylmethoxy)indoles as inhibitors of leukotriene biosynthesis
申请人:MERCK FROSST CANADA INC.
公开号:EP0535924A1
公开(公告)日:1993-04-07
Compounds having the formula I :
are inhibitors of leukotriene biosynthesis. These compounds are useful as anti-asthmatic, anti-allergic, anti-inflammatory, and cytoprotective agents. They are also useful in treating diarrhea, hypertension, angina, platelet aggregation, cerebral spasm, premature labor, spontaneous abortion, dysmenorrhea, and migraine.
具有式 I :
是白三烯生物合成的抑制剂。这些化合物可用作抗哮喘、抗过敏、抗炎和细胞保护剂。它们还可用于治疗腹泻、高血压、心绞痛、血小板聚集、脑痉挛、早产、自然流产、痛经和偏头痛。
US5273980A
申请人:——
公开号:US5273980A
公开(公告)日:1993-12-28
[EN] BENZOXAZINONE DERIVATIVES FOR THE TREATMENT OF GLYTL MEDIATED DISORDERS<br/>[FR] DÉRIVÉS DE BENZOXAZINONE POUR TRAITER DES TROUBLES INDUITS PAR GLYTL
申请人:GLAXO GROUP LTD
公开号:WO2011012622A1
公开(公告)日:2011-02-03
The present invention relates to benzoxazinone derivatives, processes for their preparation, pharmaceutical compositions and medicaments containing them and to their use in treating disorders mediated by GlyT1, including neurological and neuropsychiatric disorders, in particular psychoses, dementia or attention deficit disorder.
Substituted indoles as potent and orally active 5-lipoxygenase activating protein (FLAP) inhibitors
作者:Richard Frenette、John H. Hutchinson、Serge Léger、Michel Thérien、Christine Brideau、Chi C. Chan、Stella Charleson、Diane Ethier、Jocelyne Guay、Tom R. Jones、Malia McAuliffe、Hanna Piechuta、Denis Riendeau、Philip Tagari、Yves Girard
DOI:10.1016/s0960-894x(99)00399-6
日期:1999.8
5-lipoxygenase activating protein (FLAP) based on MK-0591. Emphasis was made on modifications to the nature of the link between the indole and the quinolinemoieties, to the substitution pattern around the two heterocycles and to possible replacements of the quinolinemoiety. Lead optimization culminated in (3-[1-(4-chlorobenzyl)-3-(t-butylthio)-5-(pyridin-2-ylmethoxy)-ind ol-2-yl]-2,2-dimethylpropanoic